Devices/Recall·openFDA/device

Boston Scientific Corporation — Class I: Boston Scientific Cardiac Resynchronization Therapy (CRT)labeled as: 1. VALITUDE CRT-P

HighPublished May 6, 2026· AI-analyzed May 11, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA has designated a Class I recall involving a software maintenance release (SMR6) for Boston Scientific VALITUDE and VISIONIST CRT-P EL devices. The advisory population has been expanded to include all CRT-P and dual-chamber extended life (DR-EL) devices within the ACCOLADE family.

Who it affects

Boston Scientific Corporation, healthcare providers utilizing VALITUDE and VISIONIST CRT-P EL models, and regulatory/QA departments overseeing cardiac rhythm management portfolios.

Why it matters

A Class I designation is the most serious recall category, indicating that the software issue could potentially cause serious health consequences. The expansion of the advisory population to include additional device models suggests that the software vulnerability or maintenance requirement is more systemic across the product family than previously identified. Regulatory teams may need to assess the effectiveness of current software deployment protocols for implanted devices.

Practical takeaway

Regulatory and QA teams should ensure that the Brady software maintenance release 6 (SMR6) is deployed to the expanded advisory population and document the update within the Quality Management System. Clinical teams should identify patients with affected CRT-P and DR-EL models to facilitate necessary software maintenance.

FDA source material

Class I. Reason: Updated software, Brady software maintenance release 6 (SMR6), is now available for the ACCOLADE" family of pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps)1 and the advisory population is expanding to include all CRT-P and dual-chamber extended life (DR-EL) devices. Dual chamber modes are specifically indicated for treatment of the following: " Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block " VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm " Low cardiac output or congestive heart failure secondary to bradycardia. Product: Boston Scientific Cardiac Resynchronization Therapy (CRT)labeled as: 1. VALITUDE CRT-P EL, Model Number U125; 2. VALITUDE CRT-P EL MRI, Model Number U128; 3. VISIONIST CRT-P EL, Model Number U225; 4. VISIONIST CRT-P EL, Model Number U226; 5. VISIONIST CRT-P EL MRI, Model Number U228.. Firm: Boston Scientific Corporation (Saint Paul MN United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.